clinical trial · NCT02193191
Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease
Sickle Cell DiseasePlerixafor
brief summary
The purpose of this research study is to test the safety and efficacy of a drug called Plerixafor. Plerixafor is approved by the US FDA for use in increasing blood stem cell counts before collection in cancer patients. It is not yet approved for patients with sickle cell disease. The investigators want to find out if Plerixafor can be used to increase cell counts in patients with sickle cell disease.
started
Sep 17, 2014
primary completion
Mar 27, 2025
completion
Mar 27, 2025
last updated
Mar 30, 2025
official title
Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol